February 08, 2019

Deal Snapshot: GlaxoSmithKline & Merck KGaA

Median deal values by quarter


  • Upfront: EUR 300M
  • Development milestones: EUR 500M
  • Commercial milestones: EUR 2900M
  • Total Deal Value: EUR 3700M
  • Royalties: Not disclosed

GlaxoSmithKline Key BD Contacts

  • Senior Vice President, Head of Business Development | Kevin Sin
  • Vice President Business Development | Ole Rasmussen
  • Senior Director Worldwide Business Development | Larry DeGraaf
  • Director of Business Development | Robert Gray
  • Director, Science and Technology Licensing, Worldwide Business Development | Alistair Morrison

GlaxoSmithKline Deal Activity by Therapeutic Area (Last 3 Years)

Recent deal activity by disease area

Recent In-Licensing Deals and Acquisitions:

GlaxoSmithKline Lead Oncology Assets

Asset Indication Stage
GSK3377794 Multiple oncology indications Phase II, Phase II, Phase II, Phase II, Phase II
GSK2857916 Multiple myeloma Phase II, Phase II, Phase II
GSK525762 Solid tumours and hematological malignancies Phase I

Business profiles tailored to your asset.